Company intelligence / Profile preview
Tris Pharma
Monmouth Junction, New Jersey, United Statestrispharma.com ↗
- Ownership
- Private
- Employees
- ~500
- Development stage
- Commercial
01
Overview
Tris Pharma has 9+ approved New Drug Applications (NDAs) and recently received FDA approval for Onyda XR, the first liquid non-stimulant nighttime treatment for ADHD in pediatric patients (May 30, 2024)[2].
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
Multiple global partnerships (specific partners not named)
Beyond the preview
Go deeper on Tris Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tris Pharma.